Direct thrombin inhibitors are superior to heparin in preventing death or myocardial infarction (MI) in patients with acute coronary syndromes (ACS), according to a meta-analysis of 11 randomized trials.

Get the latest industry news, event updates, and more from Managed healthcare Executive.

Subscribe Now!

Direct thrombin inhibitors top heparin in ACS

Newsletter